Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Gemcitabine/paclitaxel

Allergy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yang Z, et al. Clinical study of modified gemcitabine plus nab-paclitaxel in first-line treatment of unresectable advanced pancreatic cancer. [Chinese]. Journal of Practical Oncology 36: 535-541, No. 6, 10 Dec 2021. Available from: URL: http://doi.org/10.13267/j.cnki.syzlzz.2021.106 [Chinese; summarised from a translation] Yang Z, et al. Clinical study of modified gemcitabine plus nab-paclitaxel in first-line treatment of unresectable advanced pancreatic cancer. [Chinese]. Journal of Practical Oncology 36: 535-541, No. 6, 10 Dec 2021. Available from: URL: http://​doi.​org/​10.​13267/​j.​cnki.​syzlzz.​2021.​106 [Chinese; summarised from a translation]
Metadaten
Titel
Gemcitabine/paclitaxel
Allergy: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41870-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Warfarin

Case report

Tozinameran

Case report

Vemurafenib

Case report

Azd-1222

Case report

Methotrexate